Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 13/20 | 1.00 |
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSK | P43235 | 6/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 1.00 |
| ▸ | ELANE | P08246 | 2/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | CMA1 | P23946 | 1/20 | 1.00 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.90 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telaprevir SCHEMBL184177 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL19187546 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201921 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219678 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219647 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201959 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201901 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219193 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171584 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171583 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023074780-A1 | THERAPEUTIC AGENT COMPOSITION | 国立大学法人愛媛大学 | 2023-05-04 | — | — | WO | disclosed |
| US-20210052621-A1 | METHODS FOR TREATING FLAVIVIRUSES AND ZIKA INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2018136559-A1 | METHODS FOR TREATING FLAVIVIRUSES AND ZIKA INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9605018-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| CN-103554224-B | A kind of preparation method of VX-960 | 深圳翰宇药业股份有限公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-105646329-A | Method for preparing telaprevir intermediate | 重庆圣华曦药业股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160039871-A1 | NOVEL FORMS OF TELAPREVIR | SANDOZ GMBH (AT) | 2016-02-11 | — | — | US | disclosed |
| CN-103342736-B | A kind of synthetic method of VX-960 | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2016-02-10 | — | — | CN | disclosed |
| US-20100081672-A1 | PH SENSITIVE MATRIX FORMULATION | SCHERING CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20090191555-A1 | HCV NS3-NS4 Protease Resistance Mutants | VERTEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | US | disclosed |
| US-7494660-B2 | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080267915-A1 | Hcv Ns3-Ns4a Protease Inhibition | VERTEX PHARMACEUTICALS (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080267915-A1 | Hcv Ns3-Ns4a Protease Inhibition | VERTEX PHARMACEUTICALS (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070212683-A1 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070207122-A1 | COMPOSITONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | ABBOTT LABORATORIES | 2007-09-06 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039871-A1 | NOVEL FORMS OF TELAPREVIR | ACE, ACE2, CTSC | CTSB 200/4885CTSL 30/4885CTSK 64/4885 |
| US-20090191555-A1 | HCV NS3-NS4 Protease Resistance Mutants | ATG4A, CUL4A, TMPRSS4 | CTSB 175/4885CTSL 229/4885CTSK 462/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | CTSB 48/4885CTSL 17/4885CTSK 72/4885 |
| US-20070212683-A1 | Co-crystals and pharmaceutical compositions comprising the same | MLX, AGXT, CYP4X1 | CTSB 4069/4885CTSL 1924/4885CTSK 2390/4885 |
| US-20080267915-A1 | Hcv Ns3-Ns4a Protease Inhibition | SERPINB1, ERAP1, PREP | CTSB 48/4885CTSL 59/4885CTSK 290/4885 |
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | CTSB 3004/4885CTSL 2534/4885CTSK 3699/4885 |
| US-20100081672-A1 | PH SENSITIVE MATRIX FORMULATION | SI, HRH2, TMPRSS15 | CTSB 645/4885CTSL 722/4885CTSK 470/4885 |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | CTSB 14/4885CTSL 12/4885CTSK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.